Intellia Therapeutics (NTLA) Stock Forecast, Price & News

18 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Intellia Therapeutics in the last year. There are currently 3 hold ratings and 15 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NTLA shares.
View NTLA analyst ratings or view top-rated stocks.

18 brokers have issued 12-month price targets for Intellia Therapeutics' stock. Their NTLA share price forecasts range from $39.00 to $120.00. On average, they predict the company's stock price to reach $80.53 in the next twelve months. This suggests a possible upside of 85.7% from the stock's current price.
View analysts price targets for NTLA or view top-rated stocks among Wall Street analysts.

Intellia Therapeutics' stock was trading at $34.89 at the beginning of 2023. Since then, NTLA shares have increased by 24.3% and is now trading at $43.36.
View the best growth stocks for 2023 here.

Intellia Therapeutics saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 5,940,000 shares, a decline of 13.0% from the April 30th total of 6,830,000 shares. Based on an average daily volume of 1,110,000 shares, the short-interest ratio is presently 5.4 days.
View Intellia Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our NTLA earnings forecast.

Intellia Therapeutics, Inc. (NASDAQ:NTLA) issued its earnings results on Thursday, May, 4th. The company reported ($1.17) EPS for the quarter, topping analysts' consensus estimates of ($1.41) by $0.24. The business earned $12.60 million during the quarter, compared to analyst estimates of $11.76 million. Intellia Therapeutics had a negative net margin of 804.94% and a negative trailing twelve-month return on equity of 41.67%. Intellia Therapeutics's revenue was up 11.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($1.96) EPS.

ETFs with the largest weight of Intellia Therapeutics (NASDAQ:NTLA) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA), Direxion mRNA ETF (MSGR), ARK Genomic Revolution ETF (ARKG), ARK Innovation ETF (ARKK), Global X Genomics & Biotechnology ETF (GNOM), Horizon Kinetics Medical ETF (MEDX), iShares Genomics Immunology and Healthcare ETF (IDNA) and Direxion Moonshot Innovators ETF (MOON).

12 employees have rated Intellia Therapeutics Chief Executive Officer John Leonard, M.D. on Glassdoor.com. John Leonard, M.D. has an approval rating of 73% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Intellia Therapeutics investors own include Editas Medicine (EDIT), CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Alibaba Group (BABA), Block (SQ), Micron Technology (MU), Advanced Micro Devices (AMD), Intel (INTC), Invitae (NVTA) and Cisco Systems (CSCO).

(NTLA) raised $85 million in an initial public offering (IPO) on Friday, May 6th 2016. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. Credit Suisse, Jefferies and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Intellia Therapeutics trades on the NASDAQ under the ticker symbol "NTLA."

Intellia Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include ARK Investment Management LLC (11.18%), BlackRock Inc. (8.34%), State Street Corp (4.02%), Sumitomo Mitsui Trust Holdings Inc. (3.53%), Nikko Asset Management Americas Inc. (3.53%) and Wellington Management Group LLP (3.37%). Insiders that own company stock include Andrew Schiermeier, Caroline Dorsa, David Lebwohl, Glenn Goddard, Jean Francois Formela, John F Crowley, John M Leonard, John M Leonard, Jose E Rivera, Jose E Rivera, Laura Sepp-Lorenzino and Perry A Karsen.
View institutional ownership trends.

Shares of NTLA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NTLA stock can currently be purchased for approximately $43.36.

Intellia Therapeutics (NASDAQ:NTLA) has a market capitalization of $3.82 billion and generates $53.48 million in revenue each year. The company earns $-474,190,000.00 in net income (profit) each year or ($5.39) on an earnings per share basis.

The company employs 485 workers across the globe.

Intellia Therapeutics' mailing address is 40 Erie Street Suite 130, Cambridge MA, 02139. The official website for the company is www.intelliatx.com. The company can be reached via phone at (857) 285-6200 or via email at lina.li@intelliatx.com.